OBJECTIVES: Fernández Landó et al. [Diabetologia(2016) 59(Suppl 1):S1–S581] showed that patients with type 2 diabetes (T2D) treated with dulaglutide have higher adherence and persistence over 6 months vs. exenatide once weekly (EQW) or liraglutide patients. The objective of this secondary analysis was to describe diabetes-related resource utilization and costs over the same 6-month post-index period. METHODS:  This analysis utilized Truven Early View data to identify patients newly initiating GLP-1 RAs between 11/2014 and 04/2015. Index treatment was identified in hierarchical order (dulaglutide, albiglutide, EQW, exenatide twice a day, and liraglutide) with no index drug claim in the pre-index period. Patients ≥18 years old, with ≥1 medical claim with T2D diagnosis and continuous enrollment for 6 months pre- and post-index were included. Diabetes-related medical, pharmacy, and total resource utilization and costs were assessed for a propensity matched sample of patients (dulaglutide vs. liraglutide, dulaglutide vs. EQW). RESULTS:  The matched cohorts with 2,414 patients per arm for dulaglutide-EQW cohort and 2,037 for dulaglutide-liraglutide cohort were balanced in baseline demographic and clinical characteristics. The mean±SD number of prescriptions for index drug in the post-index period was higher for dulaglutide vs. EQW (4.0±2.0 vs. 2.9±1.9, p<0.0001) and dulaglutide vs. liraglutide (4.0±2.0 vs. 3.1±1.7, p<0.0001). Dulaglutide patients had similar mean±SD diabetes-related medical costs ($1,093±3,183 vs. $1,164±3,122, p=0.433) compared to EWQ patients but higher pharmacy ($4,822±2,830 vs. $4,182±2,744, p<0.0001) and total costs ($5,914±4,378 vs. $5,346±4,256, p<0.0001), likely in part due to greater number of dulaglutide prescriptions. No significant differences existed between dulaglutide vs. liraglutide patients in diabetes-related medical ($1,154±3,405 vs. $1,246±3,354, p=0.390), pharmacy ($4,719±2,784 vs. $4,551±3,091, p=0.069), and total costs ($5,873±4,529 vs. $5,797±4,872, p=0.602). CONCLUSIONS:  Dulaglutide patients have similar diabetes-related costs vs. liraglutide, and have higher pharmacy and total costs compared to EQW in part due to higher medication use, consistent with previously demonstrated higher adherence for dulaglutide.